ClinicalTrials.gg
CompletedNCT04343287Updated May 1, 2026Results posted

Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment

A Phase 2/3 interventional study of BRM421 and Placebo in Dry Eye Syndrome, sponsored by BRIM Biotechnology Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by BRIM Biotechnology Inc. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.

Enrollment
96th of 473
220 · median 60
Started
2020
with 28 others
Phase 2/3
18 of 544
none open now
Registered
334th of 544
by date

Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 96th largest by enrollment of the 473 interventional ones that give a count, is one of 29 that started in 2020, is one of 18 in phase 2/3, and was the 334th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 544 studies in Dry Eye Syndromes with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to compare the safety and efficacy of BRM421 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.

Read the detailed description

This is a multi-center, double-masked, randomized, placebo-controlled, phase 2/3 study with approximately 200 subjects. (around 100 subjects per treatment arm).

03

Conditions studied

  • Dry Eye Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be at least 18 years of age;
  • Provide written ;
  • Have a reported history of dry eye for at least 6 months prior to enrollment;
  • Have a history of use of eye drops

Exclusion criteria

Exclusion Criteria:

  • Have any slit lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters;
  • Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1;
  • Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses during the study;
  • Have used any eye drops within 2 hours of Visit 1;
  • Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months;
  • Be a woman of who is not using an acceptable means of ; acceptable methods of contraception
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
220 participants (actual)

Study arms

  • Active comparator
    BRM421 Ophthalmic Solution

    A topical solution of BRIM421 ophthalmic drops

    Drug: BRM421

  • Placebo comparator
    Placebo

    A vehicle ophthalmic drops

    Drug: Placebo

Interventions

  • DrugBRM421

    The active control with BRM421 solution

  • DrugPlacebo

    The vehicle solution

06

What researchers measure

Primary outcomes

  1. Ocular Sign: Change From Baseline in Total Corneal Staining Score to Day 14

    Corneal staining was performed to grade the degree of corneal epithelial cell injury as measured by fluorescence using slit-lamp examination. Ora Calibra® Scale from 0 to 4 with the use of half grade (0.5) increments, where grade 0 = None and 4 = Severe. Total corneal staining score was the sum of all three regions (Inferior, Central and Superior), the score range is from 0 (minimum) to 12 (maximum).

    Time frame: change from baseline to 2 weeks

  2. Ocular Symptom: Change From Baseline in Patient-Reported Ocular Dryness Score to Day 14, Using Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire

    Ocular dryness from the Ora Calibra® Ocular Discomfort \& 4-Symptom Questionnaire was assessed at the subject level in regard to how both eyes felt. The Ora Calibra® Ocular Discomfort \& 4-Symptom Questionnaire was used, which included rating the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Each symptom rating ranged from 0 to 5, where 0 = None and 5 = Worst.

    Time frame: change from baseline to 2 weeks

Secondary outcomes

  1. Eye Dryness: Change From Baseline in Patient-Reported Ocular Symptom to Day 8, Using Visual Analog Scale (VAS)

    Visual analog scale (VAS) was measured by asking subjects to rate each ocular symptom due to ocular dryness by placing a vertical mark on a horizontal line of length 100 mm to indicate the level of discomfort where 0 mm = No Discomfort and 100 mm = Maximal Discomfort. Symptoms assessed were burning/stinging, itching, foreign body sensation, blurred vision, eye dryness, photophobia, and pain.

    Time frame: change from baseline to 1 week

07

Results

Posted Oct 21, 2021

Participant flow

Participant flow — Overall Study
MilestoneBRM421 Ophthalmic SolutionPlacebo
Started108112
Completed108111
Not completed01

Outcome measures

PrimaryOcular Sign: Change From Baseline in Total Corneal Staining Score to Day 14

Corneal staining was performed to grade the degree of corneal epithelial cell injury as measured by fluorescence using slit-lamp examination. Ora Calibra® Scale from 0 to 4 with the use of half grade (0.5) increments, where grade 0 = None and 4 = Severe. Total corneal staining score was the sum of all three regions (Inferior, Central and Superior), the score range is from 0 (minimum) to 12 (maximum).

Time frame:
change from baseline to 2 weeks
Reported as:
Mean · score on a scale
Ocular Sign: Change From Baseline in Total Corneal Staining Score to Day 14
score on a scaleBRM421 Ophthalmic SolutionPlacebo
Ocular Sign: Change From Baseline in Total Corneal Staining Score to Day 14-1 ± 1.245-0.68 ± 1.392
PrimaryOcular Symptom: Change From Baseline in Patient-Reported Ocular Dryness Score to Day 14, Using Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire

Ocular dryness from the Ora Calibra® Ocular Discomfort \& 4-Symptom Questionnaire was assessed at the subject level in regard to how both eyes felt. The Ora Calibra® Ocular Discomfort \& 4-Symptom Questionnaire was used, which included rating the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Each symptom rating ranged from 0 to 5, where 0 = None and 5 = Worst.

Time frame:
change from baseline to 2 weeks
Reported as:
Mean · units on a scale
Ocular Symptom: Change From Baseline in Patient-Reported Ocular Dryness Score to Day 14, Using Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire
units on a scaleBRM421 Ophthalmic SolutionPlacebo
Ocular Symptom: Change From Baseline in Patient-Reported Ocular Dryness Score to Day 14, Using Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire-0.3 ± 0.98-0.5 ± 0.99
SecondaryEye Dryness: Change From Baseline in Patient-Reported Ocular Symptom to Day 8, Using Visual Analog Scale (VAS)

Visual analog scale (VAS) was measured by asking subjects to rate each ocular symptom due to ocular dryness by placing a vertical mark on a horizontal line of length 100 mm to indicate the level of discomfort where 0 mm = No Discomfort and 100 mm = Maximal Discomfort. Symptoms assessed were burning/stinging, itching, foreign body sensation, blurred vision, eye dryness, photophobia, and pain.

Time frame:
change from baseline to 1 week
Reported as:
Mean · score on a scale
Eye Dryness: Change From Baseline in Patient-Reported Ocular Symptom to Day 8, Using Visual Analog Scale (VAS)
score on a scaleBRM421Placebo
Eye Dryness: Change From Baseline in Patient-Reported Ocular Symptom to Day 8, Using Visual Analog Scale (VAS)-8.4 ± 19.22-3.7 ± 18.29

Adverse events

Collected over 6 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BRM421 Ophthalmic Solution0/108 (0%)1/108 (0.9%)38/108 (35.2%)
Placebo0/112 (0%)0/112 (0%)46/112 (41.1%)
Most frequent serious events
Most frequent serious events
EventBRM421 Ophthalmic SolutionPlacebo
OsteomyelitisInfections and infestations1/1080/112
Most frequent other events
Most frequent other events
EventBRM421 Ophthalmic SolutionPlacebo
instillation site painEye disorders38/10846/112

Baseline characteristics

Intent-to-treat (ITT) set included all randomized participants.

Age, Categorical
Age, Categorical(Participants)BRM421 Ophthalmic SolutionPlaceboTotal
<=18 years000
Between 18 and 65 years5057107
>=65 years5855113
Age, Continuous
Age, Continuous(years)BRM421 Ophthalmic SolutionPlaceboTotal
Mean63.9 ± 10.963.4 ± 12.0763.7 ± 11.49
Sex: Female, Male
Sex: Female, Male(Participants)BRM421 Ophthalmic SolutionPlaceboTotal
Female6983152
Male392968
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BRM421 Ophthalmic SolutionPlaceboTotal
American Indian or Alaska Native101
Asian4913
Native Hawaiian or Other Pacific Islander000
Black or African American211940
White8284166
More than one race000
Unknown or Not Reported000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BRM421 Ophthalmic SolutionPlaceboTotal
Hispanic or Latino8614
Not Hispanic or Latino100106206
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)BRM421 Ophthalmic SolutionPlaceboTotal
United States108112220
Total Corneal Fluorescein Staining
Total Corneal Fluorescein Staining(units on a scale)BRM421 Ophthalmic SolutionPlaceboTotal
Mean6.19 ± 0.9046.15 ± 0.8356.17 ± 0.868
Dryness from Ocular Discomfort & 4-Symptom Questionnaire
Dryness from Ocular Discomfort & 4-Symptom Questionnaire(units on a scale)BRM421 Ophthalmic SolutionPlaceboTotal
Mean3.0 ± 1.003.3 ± 0.933.2 ± 0.97
08

Study locations

4 sites
  • Eye Research Foundation
    Newport Beach, California 92663, United States
  • Midwest Cornea Associates, LLC
    Indianapolis, Indiana 46290, United States
  • Andover Eye Associates
    Andover, Massachusetts 01810, United States
  • Total Eye Care
    Memphis, Tennessee 38119, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Jun 2020, 5 months.

Results were first posted in Oct 2021, 1 year 3 months after primary completion.

Of 15 phase 2/3 interventional studies under Dry Eye Syndromes, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2020
First posted
Apr 13, 2020
StartActual
Jan 15, 2020
Primary completionActual
Jun 23, 2020
CompletionActual
Jun 23, 2020
Results first posted
Oct 21, 2021
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04343287
Lead sponsor
BRIM Biotechnology Inc.
Responsible party
Sponsor
First posted
Apr 13, 2020
Start date
Jan 15, 2020
Primary completion
Jun 23, 2020
Completion
Jun 23, 2020
Results posted
Oct 21, 2021
Last update
May 1, 2026

Study contacts

Gail Torkildsen, MD
principal investigator · Andover Eye Associates
Blair Boehmer, MD
principal investigator · Midwest Cornea Associates, LLC.
David Wirta, MD
principal investigator · Eye Research Foundation
Eugene B McLaurin, MD
principal investigator · Total Eye Care, PA

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fulipiftide

Start the discussion